A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting now Phase 3 NCT07522073
Run by Incyte Corporation · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Who can join (things the study team will check)
✅ You may be able to join if…
- Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation
- No prior systemic treatment in the metastatic setting
- ECOG Performance status 0-1
- Adequate organ function
🚫 You may not be able to join if…
- Prior treatment with any KRAS inhibitor
- Chronic or current active infection requiring systemic treatment within 1 week prior to the first dose of study drug
- Known active CNS metastases Other protocol-defined Inclusion/Exclusion Criteria may apply.
Where this trial is running
- Investigative Site US058, Birmingham, Alabama, United States
- Investigative Site US016, Anchorage, Alaska, United States
- Investigative Site US026, Chandler, Arizona, United States
- Investigative Site US045, Tucson, Arizona, United States
- Investigative Site US051, Duarte, California, United States
- Investigative Site US048, Fountain Valley, California, United States
- Investigative Site US049, Irvine, California, United States
- Investigative Site US054, La Jolla, California, United States
- Investigative Site US027, Los Angeles, California, United States
- Investigative Site US036, Los Angeles, California, United States
- Investigative Site US034, San Francisco, California, United States
- Investigative Site US001, Santa Monica, California, United States
+ 206 more sites.
Who to contact
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07522073.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.